Shares of Praxis Precision Medicines more than tripled Thursday, peaking at $200 apiece, after the company disclosed positive ...
The findings position Fabhalta to secure a standard approval in IgA nephropathy — a crowded area of drug research — at a time ...
The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback